GABA (GABA) News
Follow GABA (GABA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Gabather: Awaiting progress after a quiet summer
Since the start of the TOTEMS trial in May, there have been no significant news from Gabather, and the recent Q2 report held no large surprises either. The first patient has not yet been included in the trial, although h
EQUITY | Sep 07, 2026, 07:30 AM UTC
L
Gabather CEO discusses Q2 2026 results and ecosystem developments
Gabather CEO Michael-Robin Witt fields analyst questions on the Q2 2026 report and other ecosystem happenings, in a Q&A with Västra Hamnen's analyst Jacob Murat.
EARNINGS | Sep 02, 2026, 01:30 PM UTC
M
Gabather reports Q2 net sales at SEK 0
Gabather reported Q2 net sales of SEK 0.
EQUITY | Aug 31, 2026, 06:35 AM UTC
L
GABA launches first GT-002 clinical study; sleep patent filed
GABA launched its first clinical study for GT-002 and filed a new sleep treatment patent. Liquidity remains tight.
EQUITY | Aug 31, 2026, 06:33 AM UTC